Loading
A phase 3 trial of Paclitaxel / nab-paclitaxel, Carboplatin, Olaparib in ovarian cancer, run by Imunon, now recruiting.
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer is a phase 3 interventional study registered as NCT06915025 by Imunon, with 500 participants planned, started 2025-07-09 and due to reach its primary completion in 2032-10-31. Interventions recorded: IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer), Paclitaxel, Carboplatin, Olaparib, Niraparib. Conditions listed: Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Imunon, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
Shares Imunon, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
Shares Olaparib, Paclitaxel / nab-paclitaxel, Carboplatin, Ovarian cancer.
Shares Olaparib, Carboplatin, Ovarian cancer.
Shares Niraparib, Olaparib, Ovarian cancer.
Shares Niraparib, Ovarian cancer.
Shares Olaparib, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Niraparib, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/